Evidence map›Paper›PMID 42276786›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort.

Matteo Bauckneht, Liliana Belgioia, Domenico Albano, Luca Triggiani, Flavia Linguanti, Luca Urso, Rosario Mazzola, Alessio Rizzo, Elisa D'Angelo, Francesco Dondi and 33 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Matteo BaucknehtIRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy; matteo.bauckneht@unige.it.
Liliana BelgioiaIRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
Domenico AlbanoDepartment of Nuclear Medicine, ASST Spedali Civili di Brescia, Brescia, Italy.
Luca TriggianiUniversity of Brescia, Brescia, Italy.
Flavia LinguantiDepartment of Nuclear Medicine, Ospedale San Donato, Arezzo, Italy.
Luca UrsoDepartment of Nuclear Medicine, University of Ferrara, Ferrara, Italy.
Rosario MazzolaDepartment of Radiotherapy, Humanitas Gavazzeni Hospital, Bergamo, Italy.
Alessio RizzoDepartment of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Elisa D'AngeloDepartment of Radiotherapy, AUSL of Bologna, Bologna, Italy.
Francesco DondiDepartment of Nuclear Medicine, ASST Spedali Civili di Brescia, Brescia, Italy.
Eneida MatajDepartment of Radiotherapy, ASST Spedali Civili di Brescia, Brescia, Italy.
Gloria PedersoliDepartment of Radiotherapy, ASST Spedali Civili di Brescia, Brescia, Italy.
Elisabetta Maria AbenavoliDepartment of Nuclear Medicine, Careggi University Hospital, Florence, Italy.
Luca VaggelliDepartment of Nuclear Medicine, Careggi University Hospital, Florence, Italy.
Beatrice DettiDepartment of Radiotherapy, Azienda USL Centro Toscana, Prato, Italy.
Naima OrtolanDepartment of Nuclear Medicine, University of Ferrara, Ferrara, Italy.
Antonio MalorgioDepartment of Radiotherapy, University of Ferrara, Ferrara, Italy.
Alessia GuarneriDepartment of Radiotherapy, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Federico GarrouDepartment of Nuclear Medicine, ASST-Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Jacopo PassoniDepartment of Health Sciences, University of Genova, Genova, Italy.
Matilde FioriniDepartment of Advanced Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy.
Serena GrimaldiDepartment of Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
Pietro GhediniNuclear Medicine, Oncology, and Haematology Department, University of Modena, Modena, Italy.
Giuseppe Carlo IorioDepartment of Radiation Oncology, University of Turin, Turin, Italy.
Antonella IudicelloDepartment of Nuclear Medicine, University of Ferrara, Ferrara, Italy.
Guido RoveraDepartment of Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
Giuseppe FornariniIRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
Elisa ZanardiIRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
Diego BongiovanniDepartment of Radiation Oncology, University of Turin, Turin, Italy.
Michela MarcenaroIRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
Alessandra AgostiDepartment of Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
Giorgia TimonIRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
Matteo SalgarelloDepartment of Nuclear Medicine, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Italy.
Manuela RaccaNuclear Medicine Unit, A.O.U. San Luigi Gonzaga, Turin, Italy; and.
Mirco BartolomeiDepartment of Nuclear Medicine, University of Ferrara, Ferrara, Italy.
Stefano PanareoNuclear Medicine, Oncology, and Haematology Department, University of Modena, Modena, Italy.
Umberto RicardiDepartment of Radiation Oncology, University of Turin, Turin, Italy.
Francesco BertagnaDepartment of Nuclear Medicine, ASST Spedali Civili di Brescia, Brescia, Italy.
Filippo AlongiUniversity of Brescia, Brescia, Italy.
Salvina BarraIRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
Silvia MorbelliDepartment of Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
Francesco LanfranchiDepartment of Experimental Medicine, University of Genova, Genova, Italy.
Gianmario SambucetiIRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is unclear whether the imaging modality used to guide metastasis-directed therapy (MDT) influences outcomes in oligometastatic castration-resistant prostate cancer (omCRPC).

Indexed as

Positron Emission Tomography Computed TomographyProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overCholineCohort StudiesHumansMaleMiddle AgedNeoplasm MetastasisTreatment OutcomeCholinecastration-resistantoligometastaticprostate cancerPSMA PET/CTstereotactic radiotherapy

Identifiers

PMID42276786
PMCPMC13544228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.